Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Casts Wide Net For Advice on Avandia

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency increases number of voting members for the meeting of the Endocrinologic and Metabolic and Drug Safety and Risk Management Advisory Committees to 33, up 10 from 2007. Half of the committee's voting members also participated in the first review of rosiglitazone's postmarketing safety.

You may also be interested in...



Avandia Meeting Spurs New Scrutiny Of FDA Conflict-Of-Interest Screening

Revelations about speaking and consulting agreements between two FDA advisory committee members, Avandia maker GlaxoSmithKline and Actos maker Takeda, suggest the agency may need to further refine its conflict-of-interest screening procedures to ensure a public perception that it is receiving independent advice from outside experts

Avandia Meeting Spurs New Scrutiny Of FDA Conflict-Of-Interest Screening

Revelations about speaking and consulting agreements between two FDA advisory committee members, Avandia maker GlaxoSmithKline and Actos maker Takeda, suggest the agency may need to further refine its conflict-of-interest screening procedures to ensure a public perception that it is receiving independent advice from outside experts

Revenge Of The "Brain-Dead Kangaroos": Many Veterans Of 2007 Avandia Vote Come Down Harder On Drug In 2010

Accumulating negative information about the cardiovascular risks of GlaxoSmithKline's type 2 diabetes drug Avandia (rosiglitazone) led a much larger number of FDA advisory panel members to recommend taking it off the market than when the same committees met three years earlier

Related Content

Topics

UsernamePublicRestriction

Register

PS070880

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel